Docetaxel and capecitabine for advanced gastric cancer: Phase II study investigating dose dependent efficacy in two patient cohorts

Peter Thuss‐Patience(Charité - Universitätsmedizin Berlin), Peter Reichardt(Helios Hospital Berlin-Buch), B. Lebedinzew(Helios Hospital Bad Saarow), Frank Rothmann(Klinikum Ernst von Bergmann), Bernd Dörken(Charité - Universitätsmedizin Berlin), M Grothoff, I. Blau(Praxis für Hämatologie und Onkologie), Ingo Schwaner(Praxis für Hämatologie und Onkologie), Albrecht Kretzschmar(Roche (Switzerland)), Yasemin Doğan(Kayseri Eğitim ve Araştırma Hastanesi)

Journal of Clinical Oncology

May 20, 2008

10.1200/jco.2008.26.15_suppl.4551

Cited by 1

Related Papers

Perioperative chemotherapy with fluorouracil plus leucovorin, oxaliplatin, and docetaxel versus fluorouracil or capecitabine plus cisplatin and epirubicin for locally advanced, resectable gastric or gastro-oesophageal junction adenocarcinoma (FLOT4): a randomised, phase 2/3 trial

|The Lancet|2019|2.6k

Soft tissue and visceral sarcomas: ESMO–EURACAN Clinical Practice Guidelines for diagnosis, treatment and follow-up

|Annals of Oncology|2018|1.6k

Efficacy and safety of regorafenib for advanced gastrointestinal stromal tumours after failure of imatinib and sunitinib (GRID): an international, multicentre, randomised, placebo-controlled, phase 3 trial

|The Lancet|2012|1.4k

Constitutive nuclear factor-kappaB-RelA activation is required for proliferation and survival of Hodgkin's disease tumor cells.

|Journal of Clinical Investigation|1997|765

Gastrointestinal stromal tumours: ESMO–EURACAN Clinical Practice Guidelines for diagnosis, treatment and follow-up

|Annals of Oncology|2018|751